Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations

Abstract

The present invention relates to the new use of bradycardiac substances such as a Ca ++ channel blocker, beta-receptor blocker or i f channel blocker, the i f channel blockers being preferred, optionally in combination with a cardioactive substance for inducing the regression of myocardial diseases accompanied by hypertrophy, particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM) in humans and domestic pets.

1 . A pharmaceutical composition comprising cilobradine and a further cardioactive compound selected from the group consisting of: a cardioglycoside, a vasodilator, an ACE (angiotensin converting enzyme) inhibitor, an angiotensin-II antagonist, and combinations thereof.  
   
   
       2 . A pharmaceutical composition comprising cilobradine and telmisartan.